Research and Development Expenses Breakdown: Bio-Techne Corporation vs Perrigo Company plc

R&D Spending: Bio-Techne's Rise vs. Perrigo's Plateau

__timestampBio-Techne CorporationPerrigo Company plc
Wednesday, January 1, 201430945000152500000
Thursday, January 1, 201540853000187800000
Friday, January 1, 201645187000184000000
Sunday, January 1, 201753514000167700000
Monday, January 1, 201855329000218600000
Tuesday, January 1, 201962413000187400000
Wednesday, January 1, 202065192000177700000
Friday, January 1, 202170603000122000000
Saturday, January 1, 202287140000123100000
Sunday, January 1, 202392493000122500000
Monday, January 1, 202496664000
Loading chart...

In pursuit of knowledge

A Decade of Innovation: Bio-Techne vs. Perrigo

In the ever-evolving landscape of biotechnology and pharmaceuticals, research and development (R&D) expenses are a critical indicator of a company's commitment to innovation. Over the past decade, Bio-Techne Corporation and Perrigo Company plc have demonstrated contrasting trajectories in their R&D investments.

Bio-Techne has shown a remarkable upward trend, with R&D expenses growing by over 200% from 2014 to 2023. This consistent increase underscores their dedication to advancing biotechnological solutions. In contrast, Perrigo's R&D spending peaked in 2018, with a notable 43% higher investment compared to Bio-Techne that year. However, their expenses have since stabilized, reflecting a strategic shift or potential reallocation of resources.

As we look to the future, Bio-Techne's continued growth in R&D spending positions them as a formidable player in the biotech arena, while Perrigo's strategy remains to be seen.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025